CONy 2022 | The role of neuroprotectors in stroke management

Ashfaq Shuaib, MD, FRCPC, FAHA, University of Alberta Stroke Program, Alberta, Canada, comments on the use of elezenumab as a neuroprotector for patients with acute ischemic stroke. Previous research has failed to produce a successful neuroprotector, which can be administered to reduce the risk of stokes. The discovery of restrictive guidance molecule a (RGMa) as a restrictive molecule has enabled the development of novel therapies that can enhance stroke recovery. RGMa is typically only expressed as a fetal guidance molecule and only appears in patients with severe brain trauma, which can hamper recovery. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.